NASDAQ: AURA - Aura Biosciences, Inc.

Rentabilidad a seis meses: +37.13%
Sector: Healthcare

Calendario de promoción Aura Biosciences, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.

Más detalles
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

EBITDA -0.0236
Число акций ао 0.03962 млрд
P/BV 3.26
EV/EBITDA 1.37
Цена ао 7.63
ISIN US05153U1079
Сайт https://www.aurabiosciences.com
Валюта usd
IPO date 2021-10-29
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Cambio de precio por día: 0% (9.86)
Cambio de precio por semana.: +18.51% (8.32)
Cambio de precio por mes: -2.09% (10.07)
Cambio de precio en 3 meses.: +11.79% (8.82)
Cambio de precio en seis meses: +37.13% (7.19)
Cambio de precio por año: +15.73% (8.52)
Cambio de precio desde principios de año.: +23.56% (7.98)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 0 0
P/BV 1.58 8
P/E 0 0
EV/EBITDA -4 0
Total: 3.25

Eficiencia

Nombre Significado Calificación
ROA, % -29.96 0
ROE, % -33.83 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.2337 10
Total: 8.6

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 0 0
Rentabilidad Ebitda, % 254.64 10
Rentabilidad EPS, % 10.83 2
Total: 6.4
Más detalles

Instituciones Volumen Compartir, %
Matrix Capital Management 6922870 13.98
Eventide Asset Management LLC 5802682 11.72
Adage Capital Partners GP L.L.C. 4225000 8.53
Citadel Advisors Llc 3631294 7.34
Medicxi Ventures Management (Jersey) Ltd 3039892 6.14
Nantahala Capital Management, LLC 2643720 5.34
Blackrock Inc. 2098745 4.24
Vanguard Group Inc 1730431 3.5
Decheng Capital Management III (Cayman), LLC 1163123 2.35
Goldman Sachs Group Inc 1037299 2.1

ETF Compartir, % Rentabilidad del año, % Dividendos, %
Avantis International Equity ETF 0.0028 11.581970066133 3.80856
Avantis U.S Small Cap Equity ETF 0.02437 27.774101036841 1.68271
Range Cancer Therapeutics ETF 1.74943 47.24446537918 0.11955
Dimensional U.S. Core Equity 2 ETF 0.00024 30.755198832543 1.47098
Dimensional International Core Equity Market ETF 0.00084 13.085145595282 3.48343
Dimensional US Core Equity Market ETF 0.00066 30.983243755928 1.40618
Dimensional World ex U.S. Core Equity 2 ETF 0.00213 13.062098501071 3.62488
Dimensional International Core Equity 2 ETF 0.002 12.593206296603 3.69996
Dimensional International Small Cap ETF 0.02439 13.318681318681 3.34747
Dimensional U.S. Equity ETF 0.0004 31.530984204131 1.3557
AltShares Event-Driven ETF 0.97581 9.6057858816339 1.21959
DBX ETF Trust - Xtrackers International Real Estate ETF 0.06228 5.615763546798 4.01983
ProShares Hedge Replication ETF 0.0027 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.11218 34.327031588619 1.54048
iShares Russell 3000 ETF 0.00056 31.230028873917 1.43482
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund 0.01698 10.313706049416 3.85434
ProShares UltraPro Russell2000 0.00959 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 ETF 0.01 32.773459189339 1.48801



Supervisor Título profesional Pago año de nacimiento
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 895.16k 1974 (50 años)
Ms. Julie B. Feder Chief Financial Officer 604.2k 1971 (53 año)
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer N/A 1961 (63 año)
Mr. Patrick Nealon Senior Vice President of Clinical Development Operations N/A
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology N/A
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality N/A
Mr. Conor Kilroy General Counsel & Secretary N/A 1982 (42 año)
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development N/A 1965 (59 años)

DIRECCIÓN: United States, Boston. MA, 80 Guest Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.aurabiosciences.com